Core Insights - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [3] Company Overview - Keros is recognized as a leader in understanding the TGF-ß family of proteins, which are crucial for the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue [3] - The company's lead product candidate, KER-065, is aimed at treating neuromuscular diseases, specifically Duchenne muscular dystrophy [3] - Keros' most advanced product candidate, elritercept (KER-050), is being developed for treating cytopenias, such as anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis [3] Upcoming Events - Keros' Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20 a.m. Eastern time [1] - A live audio webcast of the presentation will be available, with an archived replay accessible for up to 90 days post-event [2]

LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Ba ...